BAVA:VIE
Bavarian Nordic A/S
၃၁.၉၂ €
၀.၀၀%
(၀.၀၀) 1D
အောက် ၁၅, GMT+၂ ၁၇:၃၂:၃၄ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BAVA...
Mkt. cap
၂၈၂.၈၀ ဋေ
Avg. vol.
၁၇.၀၀
Volume
၀.၀၀
52-wk high
၃၂.၄၇ €
52-wk low
၂၂.၉၆ €
No. of employees
၂ ထောင်
Mkt. cap
၂၈၂.၈၀ ဋေ
Avg. vol.
၁၇.၀၀
Volume
၀.၀၀
52-wk high
၃၂.၄၇ €
52-wk low
၂၂.၉၆ €
No. of employees
၂ ထောင်
News stories
From web sources and news partners
MarketBeat
·
ပြီးခဲ့သည့် ၁၉ မိနစ်
Chicago Atlantic BDC (NASDAQ:LIEN) Shares Up 1.2% - Time to Buy?
Yahoo Finance
·
ပြီးခဲ့သည့် ၁ နာရီ
XRP Treasury Company Evernorth Just Went Public on Nasdaq. Here's How It Could Impact the Price of XRP.
Trefis
·
ပြီးခဲ့သည့် ၅၄ မိနစ်
17 S&P 500 Stocks Just Made New 52-Week Highs
Seeking Alpha
·
ပြီးခဲ့သည့် ၁၇ နာရီ
SPYI: The Fed Raised Rates, The Gap Grew Wider And My Favorite S&P500 Income ETF Delivered
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S